Edition:
India

Edesa Biotech Inc (EDSA.OQ)

EDSA.OQ on NASDAQ Stock Exchange Capital Market

5.82USD
11 Oct 2019
Change (% chg)

$0.05 (+0.87%)
Prev Close
$5.77
Open
$5.84
Day's High
$6.02
Day's Low
$5.78
Volume
3,125
Avg. Vol
70,532
52-wk High
$13.56
52-wk Low
$0.76

Latest Key Developments (Source: Significant Developments)

Edesa Biotech Receives Approval To Initiate Clinical Study In Patients With Hemorrhoids
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Edesa Biotech Inc ::EDESA BIOTECH RECEIVES APPROVAL TO INITIATE CLINICAL STUDY IN PATIENTS WITH HEMORRHOIDS.EDESA BIOTECH INC - RECEIVED APPROVAL FROM HEALTH CANADA TO BEGIN A CLINICAL STUDY OF ITS INVESTIGATIONAL DRUG, EB02.EDESA BIOTECH INC - HEALTH CANADA REVIEWED EDESA’S CLINICAL TRIAL APPLICATION AND APPROVED IT BY ISSUING A "NO OBJECTION LETTER".EDESA BIOTECH INC - COMPANY PLANS TO ENROLL UP TO 48 PATIENTS IN THE FIRST STAGE OF THE TRIAL.  Full Article

Edesa Biotech Says Qtrly Loss Per Share $0.30
Thursday, 15 Aug 2019 

Aug 14 (Reuters) - Edesa Biotech Inc ::EDESA BIOTECH INC - REPORTS QUARTERLY FINANCIAL RESULTS.EDESA BIOTECH INC - QTRLY LOSS PER SHARE $0.30.  Full Article

Lumira Capital Investment Management Reports A 24.7% Stake In Edesa Biotech As Of June 7
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Lumira Capital Investment Management Inc::LUMIRA CAPITAL INVESTMENT MANAGEMENT INC REPORTS A 24.7% STAKE IN EDESA BIOTECH INC <<>> AS OF JUNE 7, 2019 - SEC FILING .  Full Article

Stellar Biotechnologies Reports Second Quarter Loss Per Share Of $0.31
Wednesday, 8 May 2019 

May 8 (Reuters) - Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES REPORTS SECOND QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.31.TOTAL REVENUES INCREASED BY $0.06 MILLION TO $0.12 MILLION FOR THREE MONTHS ENDED MARCH 31, 2019.  Full Article

Stellar Biotechnologies Q1 Loss Per Share $0.26
Wednesday, 6 Feb 2019 

Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.26.  Full Article

Stellar Biotechnologies - Ended Fiscal Year With More Than $10 Mln In Cash & Short-Term Investments
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES REPORTS FISCAL YEAR 2018 FINANCIAL RESULTS.STELLAR BIOTECHNOLOGIES INC - ENDED FISCAL YEAR WITH MORE THAN $10 MILLION IN CASH AND SHORT-TERM INVESTMENTS.  Full Article

Stellar Biotechnologies Announces Pricing Of $5.5 Mln Public Offering
Friday, 11 May 2018 

May 11 (Reuters) - Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES ANNOUNCES PRICING OF $5.5 MILLION PUBLIC OFFERING.STELLAR BIOTECHNOLOGIES INC - STELLAR IS OFFERING UNITS AT A PRICE OF $2.65 PER UNIT.STELLAR BIOTECHNOLOGIES INC - ANNOUNCED PRICING OF A PUBLIC OFFERING OF AN AGGREGATE OF 2.1 MILLION UNITS.  Full Article

Stellar Biotechnologies Reports Q1 Loss Per Share $0.13
Thursday, 8 Feb 2018 

Feb 7 (Reuters) - Stellar Biotechnologies Inc ::STELLAR BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.13.‍TOTAL REVENUES FOR QUARTER ENDED DECEMBER 31, 2017 WERE $.02 MILLION COMPARED TO $.14 MILLION FOR SAME PERIOD IN 2016​.  Full Article

No consensus analysis data available.